Daiichi Industrial Pharmaceutical revised its full-year consolidated earnings forecast for the fiscal year ending March 2027 to sales of \u00a55.2 billion (up 26.8% from the previous forecast), with a significant upward revision of profits. The strong performance in the second quarter is expected to lead to an outlook exceeding the full-year forecast.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4461","jir_company_name":"Daiichi Industrial Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2605","jir_publication_date":"2026-07-29","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/07\/4461-20260729-02.pdf","jir_short_summary":"Daiichi Industrial Pharmaceutical revised its full-year consolidated earnings forecast for the fiscal year ending March 2027 to sales of \u00a55.2 billion (up 26.8% from the previous forecast), with a significant upward revision of profits. The strong performance in the second quarter is expected to lead to an outlook exceeding the full-year forecast.","jir_summary":"### Overview of Performance\nDaiichi Industrial Pharmaceutical revised its full-year earnings forecast for the fiscal year ending March 2027 during the second quarter, projecting substantial increases in sales and profits driven by growth in the Electronics & Information segment and the Environment & Energy segment for high value-added products. Sales are expected to reach \u00a552,000 million (up 26.8% YoY), operating income \u00a57,500 million (up 50.0%), and net income \u00a54,700 million (up 56.7%). These results are primarily due to price revisions and temporary demand increases, and ongoing attention to external factors affecting the business environment is necessary.\n\n### Outlook and Impact on Shareholders\nThe upward revision of the full-year outlook anticipates increases in sales and profits, likely leading to positive effects on dividends and stock prices for shareholders. However, considering external factors such as Middle East geopolitical developments and currency fluctuations, the company will continue to operate cautiously. Backed by strong second-quarter results, Daiichi Industrial Pharmaceutical aims to expand sales of high value-added products and implement pricing strategies to achieve sustainable growth.","jir_financial_highlights":"Net Sales: \u00a552,000 million (Up 26.8% from the previous forecast)\nOperating Income: \u00a57,500 million (Up 50.0% from the previous forecast)\nOrdinary Income: \u00a57,600 million (Up 52.0% from the previous forecast)\nNet Income Attributable to Owners of Parent: \u00a54,700 million (Up 56.7% from the previous forecast)\nEarnings per Share: 442.94 yen (Up 56.7% from the previous forecast)","jir_category":"","jir_hashtags":"#DaiichiIndustrialPharmaceutical, #IR, #JapanStocks","jir_key_figures":"Net Sales: \u00a552,000 million (Up 26.8% from the previous forecast)\nOperating Income: \u00a57,500 million (Up 50.0% from the previous forecast)\nNet Income Attributable to Owners of Parent: \u00a54,700 million (Up 56.7% from the previous forecast)","jir_meta_title":"[Daiichi Industrial Pharmaceutical] Revision of Full-Year Earnings Forecast for 2027 | Sales of \u00a55.2 billion (Up 26.8% YoY)","jir_meta_description":"Daiichi Industrial Pharmaceutical revised its full-year earnings forecast for fiscal year ending March 2027 to sales of \u00a55.2 billion, with a significant upward revision of profits. An overview of future business outlook and impact on shareholders is provided.","jir_og_title":"[Daiichi Industrial Pharmaceutical] Revision of Full-Year Earnings Forecast for 2027 | Sales of \u00a55.2 billion","jir_og_description":"Daiichi Industrial Pharmaceutical significantly upwardly revised its earnings forecast for fiscal year 2027. Details on future business strategies and shareholder impact are elaborated.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":16712,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-89681","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n